Evidence map›Paper›PMID 42061408›Full record

ArticleCell reports. Medicine2026

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Pradip Bajgain, Yang Feng, Mariela Puebla, Meijie Tian, Kuo-Sheng Hsu, Jaewon Lee, GuoJun Yu, Liping Yang, Steven Seaman, Mary Beth Hilton and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Pradip BajgainTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Yang FengTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Mariela PueblaPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Meijie TianOncogenenomics Section, Genetics Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Kuo-Sheng HsuTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Jaewon LeeTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
GuoJun YuTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Liping YangTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Steven SeamanTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.
Mary Beth HiltonTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA; Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, MD 21702, USA.
Karen MorrisTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA; Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, MD 21702, USA.
Niza BorchinTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA; Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, MD 21702, USA.
Jennifer D TranPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Riley D MetcalfeCenter for Structural Biology, CCR, NCI, NIH, Frederick, MD 21702, USA.
Dan LiLaboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Mitchell HoLaboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
James C CronkPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Javed KhanOncogenenomics Section, Genetics Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Anandani NellanPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Rosandra N KaplanPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Brad St CroixTumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA. Electronic address: stcroixb@mail.nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B7-H3 is a cell surface protein overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR) T cell therapy. The most clinically advanced B7-H3 CARs derive from murine monoclonal antibodies (mAbs) 376.96 and MGA271 and are now in phase 1/2 trials. However, non-human mAb sequences can provoke immune responses, leading to CAR T cell rejection and therapeutic failure. Although single-chain variable fragment (scFv) humanization reduces this risk, residual foreign residues within variable domains remain. To overcome this limitation, here we use in vitro phage display to generate fully human B7-H3-specific scFvs for CAR design. In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 are well tolerated and demonstrate superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induces complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.

Indexed as

B7 AntigensImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorFemaleHumansMiceSingle-Chain AntibodiesXenograft Model Antitumor AssaysB7 AntigensCD276 protein, humanReceptors, Chimeric AntigenSingle-Chain Antibodiesadoptive T cell transferB7-H3B7H3CARCD276chimeric antigen receptorfully human antibodyglioblastomaneuroblastomapancreatic ductal adenocarcinomaphage display library

Identifiers

PMID42061408
PMCPMC13198247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.